Meeting the challenge of chronic ischaemic heart disease with trimetazidine

Related Experiment Video

Updated: Aug 14, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Mario Marzilli1, Silvia Affinito

  • 1Postgraduate School of Cardiology, University of Siena, Italy. marzilli@unisi.it

Coronary Artery Disease
|December 13, 2005
PubMed

Insights

Diabetic patients face high cardiovascular risks, similar to those with prior heart disease. Novel metabolic therapies, like trimetazidine, show promise for managing ischemic heart disease in this population.

Area of Science:

  • Cardiology
  • Diabetology
  • Pharmacology

Background:

  • Cardiovascular events risk in diabetic patients mirrors that of patients with prior ischemic heart disease.
  • Ischemic heart disease prevalence is rapidly increasing in diabetic patients.
  • Standard treatments for ischemic heart disease are less effective in diabetic individuals.

Purpose of the Study:

  • To explore alternative therapeutic strategies for managing ischemic heart disease in diabetic patients.
  • To investigate the potential of directly modulating cardiac metabolic alterations in diabetes.

Main Methods:

  • Review of existing therapeutic options including antianginal agents, percutaneous transluminal coronary angioplasty, and aorto-coronary by-pass surgery.
  • Evaluation of metabolic agents targeting cardiac metabolic alterations.

Main Results:

  • Conventional treatments demonstrate reduced efficacy in diabetic patients.
  • The metabolic agent trimetazidine has shown promising results in anginal patients.

Conclusions:

  • Direct modulation of cardiac metabolic alterations presents a promising therapeutic avenue.
  • Trimetazidine's efficacy in anginal patients supports its potential for managing ischemic heart disease in diabetes.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...